Cargando…
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829086/ https://www.ncbi.nlm.nih.gov/pubmed/29527515 http://dx.doi.org/10.3389/fonc.2018.00040 |
_version_ | 1783302732779618304 |
---|---|
author | Oehl, Kathrin Kresoja-Rakic, Jelena Opitz, Isabelle Vrugt, Bart Weder, Walter Stahel, Rolf Wild, Peter Felley-Bosco, Emanuela |
author_facet | Oehl, Kathrin Kresoja-Rakic, Jelena Opitz, Isabelle Vrugt, Bart Weder, Walter Stahel, Rolf Wild, Peter Felley-Bosco, Emanuela |
author_sort | Oehl, Kathrin |
collection | PubMed |
description | Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained in vitro, providing a useful tool to investigate underlying mechanisms. Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naive patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort. Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed in vivo, which eventually may lead to a more logical approach for developing new treatment strategies. |
format | Online Article Text |
id | pubmed-5829086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58290862018-03-09 Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression Oehl, Kathrin Kresoja-Rakic, Jelena Opitz, Isabelle Vrugt, Bart Weder, Walter Stahel, Rolf Wild, Peter Felley-Bosco, Emanuela Front Oncol Oncology Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained in vitro, providing a useful tool to investigate underlying mechanisms. Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naive patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort. Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed in vivo, which eventually may lead to a more logical approach for developing new treatment strategies. Frontiers Media S.A. 2018-02-23 /pmc/articles/PMC5829086/ /pubmed/29527515 http://dx.doi.org/10.3389/fonc.2018.00040 Text en Copyright © 2018 Oehl, Kresoja-Rakic, Opitz, Vrugt, Weder, Stahel, Wild and Felley-Bosco. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Oehl, Kathrin Kresoja-Rakic, Jelena Opitz, Isabelle Vrugt, Bart Weder, Walter Stahel, Rolf Wild, Peter Felley-Bosco, Emanuela Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression |
title | Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression |
title_full | Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression |
title_fullStr | Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression |
title_full_unstemmed | Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression |
title_short | Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression |
title_sort | live-cell mesothelioma biobank to explore mechanisms of tumor progression |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829086/ https://www.ncbi.nlm.nih.gov/pubmed/29527515 http://dx.doi.org/10.3389/fonc.2018.00040 |
work_keys_str_mv | AT oehlkathrin livecellmesotheliomabiobanktoexploremechanismsoftumorprogression AT kresojarakicjelena livecellmesotheliomabiobanktoexploremechanismsoftumorprogression AT opitzisabelle livecellmesotheliomabiobanktoexploremechanismsoftumorprogression AT vrugtbart livecellmesotheliomabiobanktoexploremechanismsoftumorprogression AT wederwalter livecellmesotheliomabiobanktoexploremechanismsoftumorprogression AT stahelrolf livecellmesotheliomabiobanktoexploremechanismsoftumorprogression AT wildpeter livecellmesotheliomabiobanktoexploremechanismsoftumorprogression AT felleyboscoemanuela livecellmesotheliomabiobanktoexploremechanismsoftumorprogression |